INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 433m ago
HOUSE PTR33m ago
SEC 13F33m ago
ROBINHOOD CHAIN33m ago
SEC FORM 4/Grant or awardVerified data

Casale Donn reported SPRY

President · ARS Pharmaceuticals, Inc. · ARS Pharmaceuticals, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
898.5K
Price
—
Executed
Jul 1, 2026
Disclosed
Jul 2, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jul 1 executedJul 2, 2026 disclosed

SPRY · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SPRY

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SL
    Slebir John LChief Legal Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.20M sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CD
    Casale DonnDirector, President and CEO
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.04M sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SE
    Smith Margaret EkinsChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    1.00M sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    KM
    Kelly MichaelDirector
    SPRYARS Pharmaceuticals, Inc.
    Grant or award
    		A—
    30.0K sh
    		Jun 24, 2026Jun 26, 2026
    traded Jun 24, 2026
    		+2dSEC FORM 4

    Evidence

    23
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    3
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M—
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    11
    KE
    Karas EricChief Commercial Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise · 10b5-1 plan
    		M$38K
    25.0K sh
    		Jun 12, 2026Jun 12, 2026
    traded Jun 12, 2026
    		+0dSEC FORM 4

    Evidence

    31
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$267K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    21
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise
    		M—
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    42
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Open-market sale
    		SELL$1.21M
    136.4K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    17
    CJ
    Chakma JustinChief Business Officer
    SPRYARS Pharmaceuticals, Inc.
    Option exercise
    		M$25K
    30.0K sh
    		Nov 12, 2025Nov 14, 2025
    traded Nov 12, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002135296-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jul 1, 2026
    Published
    Jul 2, 2026
    Ingested by INSIDER
    Nov 5, 03:49 UTC
    Last re-read
    Nov 5, 03:49 UTC

    Extracted facts

    Filer
    Casale Donn
    Role
    President
    Transaction
    Grant or awardAs filed: “A”
    Asset
    ARS Pharmaceuticals, Inc. — Stock Option (right to buy)
    Ticker
    SPRY
    Shares
    898.5K
    Price per share
    $0
    Execution date (reported)
    Jul 1, 2026
    Owned after transaction
    898.5K shares
    Days from execution to publication
    1

    What this establishes

    Casale Donn filed this Form 4 reporting a grant or award of SPRY on Jul 1, 2026. It became public on Jul 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    President
    Casale Donncik:0002135296
    Issuer
    ARS Pharmaceuticals, Inc.cik:0001671858

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.